Last reviewed · How we verify
ALZ002 DS
At a glance
| Generic name | ALZ002 DS |
|---|---|
| Also known as | JM17 |
| Sponsor | AnnJi Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALZ002 DS CI brief — competitive landscape report
- ALZ002 DS updates RSS · CI watch RSS
- AnnJi Pharmaceutical Co., Ltd. portfolio CI